Biotech set to regain favour after recent thrills and spills...

Biotech set to regain favour after recent thrills and spills
http://www.smh.com.au/business/biot...d-spills-20170104-gtm71i.html?deviceType=text
The last few months have been ones to forget for biotech shares with a rotation of funds out of the sector globally leaving many stocks in the sector well down on their 12-month highs, with sentiment also hurt amid caution the US will force drug prices lower which will hit earnings.
...
At Bell Potter, its biotech analyst Tanushree Jain likes Medical Developments with its pain relief device, along with Opthea, Mesoblast, Bionomics and Starpharma, which are all in focus for the year ahead, even with the knocks the shares in Mesoblast and Bionomics have suffered, with Medical Developments, too, pulled well off its highs by the end of 2016.